The supply agreement reflects Moderna’s commitment to making its vaccine available in Africa. Botswana Medicines Regulatory Authority issues emergency use authorisation (EUA) for COVID-19 Vaccine Moderna.
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced on Thursday a supply agreement with the Government of the Republic of Botswana for Moderna’s vaccine against COVID-19, to support the Government’s ongoing efforts to secure access to COVID-19 vaccines for the people of Botswana. The Company also announced that the Botswana Medicines Regulatory Authority (BOMRA) has issued an emergency use authorisation for the COVID-19 Vaccine Moderna.
“We appreciate the collaboration with the Government of the Republic of Botswana for this supply agreement and with the Botswana Medicines Regulatory Authority for this EUA,” said Stéphane Bancel, Moderna’s Chief Executive Officer.
“We are committed to ensuring that people on every continent have access to our mRNA vaccine so that we can defeat the COVID-19 pandemic.”
This agreement with Botswana is separate from the supply agreement with Gavi, the Vaccine Alliance, which Moderna announced in May. The agreement with Gavi, on behalf of the COVAX Facility, is for the supply of up to 500 million doses of the COVID-19 Vaccine Moderna, including an initial 34 million doses to be delivered in the fourth quarter of 2021. COVAX is a global initiative co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organization (WHO), to ensure equitable access to COVID-19 vaccines for all countries, regardless of income levels.
